Diamyd Medical AB (publ) Cash Flow Conversion Efficiency
Diamyd Medical AB (publ) cash flow conversion efficiency. Based on the latest financial reports, Diamyd Medical AB (publ) (DMYD-B) has a cash flow conversion efficiency ratio of -0.276x as of May 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-71.70 Million ≈ $-7.72 Million USD) by net assets (Skr259.39 Million ≈ $27.91 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Diamyd Medical AB (publ) (2010–2025)
Cash flow conversion efficiency of Diamyd Medical AB (publ) from 2010 to 2025. This chart illustrates how Diamyd Medical AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Diamyd Medical AB (publ) for real-time trading data and today's change.
Diamyd Medical AB (publ) Cash Flow Conversion Ratio Explained
Diamyd Medical AB (publ) cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Diamyd Medical AB (publ) Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Diamyd Medical AB (publ) ranked by their cash flow conversion efficiency. Also see DMYD-B market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
New Bubbleroom Sweden AB
ST:BBROOM
|
0.097x |
|
Baid Finserv Limited
NSE:BAIDFIN
|
0.008x |
|
OURGAME INT.HOL.DL-00005
F:13O
|
N/A |
|
Neuphoria Therapeutics Inc
NASDAQ:NEUP
|
0.048x |
|
High-Tek Harness Enterprise Co Ltd
TWO:3202
|
0.014x |
|
Adler Group SA
F:ADJ
|
-0.053x |
|
Firebird Metals Ltd
AU:FRB
|
-0.086x |
|
Canadian North Resources Inc.
V:CNRI
|
0.006x |
Annual Cash Flow Conversion Efficiency for Diamyd Medical AB (publ) (2010–2025)
The table below shows the annual cash flow conversion efficiency of Diamyd Medical AB (publ) from 2010 to 2025. Review Diamyd Medical AB (publ) free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-08-31 | Skr280.00 Million ≈ $30.13 Million |
Skr-169.68 Million ≈ $-18.26 Million |
-0.606x | +31.55% |
| 2024-08-31 | Skr145.92 Million ≈ $15.70 Million |
Skr-129.18 Million ≈ $-13.90 Million |
-0.885x | -35.15% |
| 2023-08-31 | Skr169.40 Million ≈ $18.23 Million |
Skr-110.96 Million ≈ $-11.94 Million |
-0.655x | -50.64% |
| 2022-08-31 | Skr214.38 Million ≈ $23.07 Million |
Skr-93.22 Million ≈ $-10.03 Million |
-0.435x | +24.82% |
| 2021-08-31 | Skr189.26 Million ≈ $20.37 Million |
Skr-109.47 Million ≈ $-11.78 Million |
-0.578x | -348.38% |
| 2020-08-31 | Skr72.49 Million ≈ $7.80 Million |
Skr16.88 Million ≈ $1.82 Million |
0.233x | +137.31% |
| 2019-08-31 | Skr62.78 Million ≈ $6.76 Million |
Skr-39.19 Million ≈ $-4.22 Million |
-0.624x | +35.41% |
| 2018-08-31 | Skr43.01 Million ≈ $4.63 Million |
Skr-41.56 Million ≈ $-4.47 Million |
-0.966x | -224.51% |
| 2017-08-31 | Skr86.67 Million ≈ $9.33 Million |
Skr-25.81 Million ≈ $-2.78 Million |
-0.298x | +50.91% |
| 2016-08-31 | Skr29.26 Million ≈ $3.15 Million |
Skr-17.75 Million ≈ $-1.91 Million |
-0.607x | -30.94% |
| 2015-08-31 | Skr39.52 Million ≈ $4.25 Million |
Skr-18.31 Million ≈ $-1.97 Million |
-0.463x | -22.60% |
| 2014-08-31 | Skr44.16 Million ≈ $4.75 Million |
Skr-16.69 Million ≈ $-1.80 Million |
-0.378x | -66.13% |
| 2013-08-31 | Skr60.29 Million ≈ $6.49 Million |
Skr-13.71 Million ≈ $-1.48 Million |
-0.227x | -66.41% |
| 2012-08-31 | Skr409.58 Million ≈ $44.08 Million |
Skr-55.99 Million ≈ $-6.03 Million |
-0.137x | +32.98% |
| 2011-08-31 | Skr460.97 Million ≈ $49.61 Million |
Skr-94.03 Million ≈ $-10.12 Million |
-0.204x | -128.44% |
| 2010-08-31 | Skr314.78 Million ≈ $33.88 Million |
Skr225.77 Million ≈ $24.30 Million |
0.717x | -- |
About Diamyd Medical AB (publ)
Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes in adults (LADA); and Remygen, an immunomodulation therapy, that is in phase I/II clinical trial for the treatment of with ty… Read more